Quantcast

Latest Treatments of Parkinson's Disease Stories

2011-02-15 06:00:00

SAN DIEGO, Feb. 15, 2011 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, reported today that its scientists and collaborators have published new experimental findings in support of its Parkinson's disease program which appeared as the lead article in the current issue of Movement Disorders (the official journal of the Movement Disorders Society). The publication reports the first evidence that gene transfer can provide targeted expression of a neurotrophic factor, i.e.,...

2011-02-03 08:00:00

SAN DIEGO, Feb. 3, 2011 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, announced today that it is progressing with enrollment and dosing in its CERE-120 (AAV2-neurturin) Phase 2b multi-center, sham-surgery, double-blinded controlled trial in Parkinson's disease. This trial was initiated in October 2010 and all 11 centers across the United States are now actively enrolling patients. These sites are among the best movement disorders centers in the country and include Baylor...

2010-10-06 07:45:00

NESS ZIONA, Israel, October 6, 2010 /PRNewswire/ -- NeuroDerm, Ltd. was informed today that it was awarded a grant of $1M by The Michael J. Fox Foundation for Parkinson's Research. These funds will support the next clinical study with ND0611, a new dermal patch for the treatment of Parkinson's disease, as part of the Foundation's prestigious Clinical Intervention Awards 2010 program. This study will evaluate the safety, tolerability, levodopa pharmacokinetics, and possible clinical...

2010-10-01 10:00:00

FORT LEE, N.J., Oct. 1 /PRNewswire-FirstCall/ -- Neurologix, Inc. (OTC Bulletin Board: NRGX), today announced that new details of the company's landmark, randomized, double-blind Phase 2 clinical trial of NLX-P101, its investigational gene therapy for advanced Parkinson's disease (PD), were presented during a symposium at the 2nd World Parkinson Congress in Glasgow, Scotland. Co-principal investigator of the trial, Dr. Peter Lewitt, Director of the Parkinson's Disease and Movement...

2010-10-01 06:30:00

NEW YORK, Oct. 1 /PRNewswire/ -- Intra-Cellular Therapies, Inc. today announced results from studies demonstrating the anti-Parkinson and other beneficial effects of ITI-002 (IC200214), the Company's novel and selective phosphodiesterase type I (PDE1) inhibitor. Intra-Cellular Therapies presented preclinical data at the 2nd World Parkinson Congress held in Glasgow, Scotland, demonstrating ITI-002 was effective in improving motor and non-motor behaviors relevant to the treatment of...

2010-09-28 06:58:00

NESS ZIONA, Israel, September 28, 2010 /PRNewswire/ -- NeuroDerm, Ltd. announce today that a platform presentation highlighting the company's new dermal patch for the treatment of Parkinson's disease, ND0611, was given yesterday at the 14th Congress of the European Federation of Neurological Societies in Geneva, Switzerland. A poster presentation will be given at the 2nd World Parkinson's Congress in Glasgow, Scotland. (Sep 28th - Oct 1st, 2010). The presentation described results of...

2010-07-01 12:02:00

RICHMOND, Calif., July 1 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that it has been awarded a second round of funding by The Michael J. Fox Foundation for Parkinson's Research (MJFF) to support studies in non-human primates for the development of a ZFP Therapeutic(TM) to treat Parkinson's disease (PD). The $900,000 award will be paid over a period of two years. Sangamo has developed zinc finger DNA-binding protein transcription factors (ZFP TFs)...

2010-07-01 12:00:00

NEW YORK, July 1 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research has awarded research teams at eight biotech and pharmaceutical companies a total of $3 million for pre-clinical Parkinson's drug development projects. Funded investigations aim to push forward approaches that could slow or stop progression of the disease, alleviate symptoms or refine existing therapies. MJFF welcomes industry researchers to apply for funding under any of its programs and has...

2010-06-22 07:30:00

FORT LEE, N.J., June 22 /PRNewswire-FirstCall/ -- Neurologix, Inc. (OTC Bulletin Board: NRGX), today announced positive results in a Phase 2 trial of its investigational gene therapy for advanced Parkinson's disease (PD), NLX-P101. Study participants who received NLX-P101 experienced statistically significant and clinically meaningful improvements in off-medication motor scores compared to control subjects who received sham surgery. In the trial, this benefit was seen at one month and...

2010-06-01 05:59:00

NESS ZIONA, Israel, June 1, 2010 /PRNewswire/ -- NeuroDerm, Ltd. announced today the successful enrollment and dosing in its Phase I clinical trial of ND0611. ND0611, a proprietary drug formula administered via a dermal patch, is designed to maintain continuous therapeutic levodopa concentrations for improving the treatment of Parkinson's disease. ND0611 increases levodopa bioavailability and extends its effects by administering a novel pharmaceutical. Previous animal studies found...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related